{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:19:45Z","timestamp":1785853185187,"version":"3.56.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T00:00:00Z","timestamp":1652572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T00:00:00Z","timestamp":1652572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100016947","name":"Swim Across America","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016947","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100014082","name":"Rhode Island Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014082","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-022-01665-4","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T15:27:03Z","timestamp":1653060423000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A bioinformatic analysis of WFDC2 (HE4) expression in high grade serous ovarian cancer reveals tumor-specific changes in metabolic and extracellular matrix gene expression"],"prefix":"10.1007","volume":"39","author":[{"given":"Nicole E.","family":"James","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Gura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Woodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard N.","family":"Freiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1685-8568","authenticated-orcid":false,"given":"Jennifer R.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,15]]},"reference":[{"key":"1665_CR1","first-page":"3695","volume":"63","author":"I Hellstr\u00f6m","year":"2003","unstructured":"Hellstr\u00f6m I, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63:3695\u2013700.","journal-title":"Cancer Res"},{"key":"1665_CR2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","volume":"112","author":"RG Moore","year":"2009","unstructured":"Moore RG, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40\u20136.","journal-title":"Gynecol Oncol"},{"key":"1665_CR3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fonc.2018.00124","volume":"8","author":"NE James","year":"2018","unstructured":"James NE, et al. Beyond the biomarker: understanding the diverse roles of human epididymis protein 4 in the pathogenesis of epithelial ovarian cancer. Front Oncol. 2018;8:124.","journal-title":"Front Oncol"},{"key":"1665_CR4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13048-016-0240-0","volume":"9","author":"JR Ribeiro","year":"2016","unstructured":"Ribeiro JR, et al. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells. J Ovarian Res. 2016;9:28.","journal-title":"J Ovarian Res"},{"key":"1665_CR5","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3389\/fonc.2017.00332","volume":"7","author":"JR Ribeiro","year":"2017","unstructured":"Ribeiro JR, et al. Human epididymis protein 4 promotes events associated with metastatic ovarian cancerviaregulation of the extracelluar matrix. Front Oncol. 2017;7:332.","journal-title":"Front Oncol"},{"key":"1665_CR6","doi-asserted-by":"crossref","first-page":"8558","DOI":"10.1038\/s41598-020-65353-x","volume":"10","author":"NE James","year":"2020","unstructured":"James NE, et al. The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes. Sci Rep. 2020;10:8558.","journal-title":"Sci Rep"},{"key":"1665_CR7","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1078-0432.CCR-19-0603","volume":"26","author":"CW McCloskey","year":"2020","unstructured":"McCloskey CW, et al. Metformin abrogates age-associated ovarian fibrosis. Clin Cancer Res. 2020;26:632\u201342.","journal-title":"Clin Cancer Res"},{"key":"1665_CR8","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3390\/cancers10110406","volume":"10","author":"S Dasari","year":"2018","unstructured":"Dasari S, et al. Cancer associated fibroblasts: naughty neighbors that drive ovarian cancer progression. Cancers (Basel). 2018;10:406.","journal-title":"Cancers (Basel)"},{"key":"1665_CR9","doi-asserted-by":"crossref","first-page":"e20192312","DOI":"10.1084\/jem.20192312","volume":"217","author":"X Ma","year":"2020","unstructured":"Ma X. The omentum, a niche for premetastatic ovarian cancer. J Exp Med. 2020;217:e20192312.","journal-title":"J. Exp. Med."},{"key":"1665_CR10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1465-9921-7-61","volume":"7","author":"L Bingle","year":"2006","unstructured":"Bingle L, et al. WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res. 2006;7:61.","journal-title":"Respir Res"},{"key":"1665_CR11","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/sj.onc.1205363","volume":"21","author":"L Bingle","year":"2002","unstructured":"Bingle L, et al. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene. 2002;21:2768\u201373.","journal-title":"Oncogene"},{"key":"1665_CR12","doi-asserted-by":"crossref","first-page":"e47672","DOI":"10.1371\/journal.pone.0047672","volume":"7","author":"N Chhikara","year":"2012","unstructured":"Chhikara N, et al. Human epididymis protein-4 (HE-4): a novel cross-class protease inhibitor. PLoS One. 2012;7:e47672.","journal-title":"PLoS One"},{"key":"1665_CR13","unstructured":"Nagy, B. et al. (2016) Serum HE4 is a suitable inflammatory biomarker in cystic fibrosis: YF8. Clin Chem Lab Med"},{"key":"1665_CR14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jcf.2018.08.013","volume":"18","author":"B Nagy","year":"2019","unstructured":"Nagy B, et al. Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment. J Cyst Fibros. 2019;18:271\u20137.","journal-title":"J Cyst Fibros"},{"key":"1665_CR15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nm.2989","volume":"19","author":"VS LeBleu","year":"2013","unstructured":"LeBleu VS, et al. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat Med. 2013;19:227\u201331.","journal-title":"Nat Med"},{"key":"1665_CR16","doi-asserted-by":"crossref","first-page":"e23428","DOI":"10.1097\/MD.0000000000023428","volume":"99","author":"Y Hou","year":"2020","unstructured":"Hou Y, et al. Clinical significance of serum human epididymis protein 4 in liver fibrosis: an experimental study. Medicine (Baltimore). 2020;99:e23428.","journal-title":"Medicine (Baltimore)"},{"key":"1665_CR17","doi-asserted-by":"crossref","first-page":"67748","DOI":"10.18632\/oncotarget.11682","volume":"7","author":"J Wan","year":"2016","unstructured":"Wan J, et al. Elevated serum concentrations of HE4 as a novel biomarker of disease severity and renal fibrosis in kidney disease. Oncotarget. 2016;7:67748\u201359.","journal-title":"Oncotarget"},{"key":"1665_CR18","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.7150\/ijms.50491","volume":"17","author":"J Liu","year":"2020","unstructured":"Liu J, et al. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database. Int J Med Sci. 2020;17:3200\u201313.","journal-title":"Int J Med Sci"},{"key":"1665_CR19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7314\/APJCP.2014.15.1.101","volume":"15","author":"WT Chen","year":"2014","unstructured":"Chen W-T, et al. HE4 as a serum biomarker for ROMA prediction and prognosis of epithelial ovarian cancer. Asian Pac J Cancer Prev. 2014;15(1):101\u2013105.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1665_CR20","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ygyno.2011.04.052","volume":"122","author":"E Hoskins","year":"2011","unstructured":"Hoskins E, et al. Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells. Gynecol Oncol. 2011;122:656\u201362.","journal-title":"Gynecol Oncol"},{"key":"1665_CR21","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1349-7006.2009.01076.x","volume":"100","author":"N Devoogdt","year":"2009","unstructured":"Devoogdt N, et al. Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo. Cancer Sci. 2009;100:434\u201340.","journal-title":"Cancer Sci"},{"key":"1665_CR22","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/carcin\/bgm212","volume":"29","author":"FA Simpkins","year":"2008","unstructured":"Simpkins FA, et al. The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells. Carcinogenesis. 2008;29:466\u201372.","journal-title":"Carcinogenesis"},{"key":"1665_CR23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/onc.2013.562","volume":"34","author":"SI Labidi-Galy","year":"2015","unstructured":"Labidi-Galy SI, et al. Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. Oncogene. 2015;34:373\u201383.","journal-title":"Oncogene"},{"key":"1665_CR24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1593\/neo.91542","volume":"12","author":"A Clauss","year":"2010","unstructured":"Clauss A, et al. Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. Neoplasia. 2010;12:161\u201372.","journal-title":"Neoplasia"},{"key":"1665_CR25","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1074\/jbc.M109.073494","volume":"285","author":"B Su","year":"2010","unstructured":"Su B, et al. SSeCKS\/Gravin\/AKAP12 inhibits cancer cell invasiveness and chemotaxis by suppressing a protein kinase C- Raf\/MEK\/ERK pathway. J Biol Chem. 2010;285:4578\u201386.","journal-title":"J Biol Chem"},{"key":"1665_CR26","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1096\/fj.201901950R","volume":"34","author":"L Zhang","year":"2020","unstructured":"Zhang L, et al. Hypoxia-induced HE4 in tubular epithelial cells promotes extracellular matrix accumulation and renal fibrosis via NF-\u03baB. FASEB J. 2020;34:2554\u201367.","journal-title":"FASEB J"},{"key":"1665_CR27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.omto.2018.11.004","volume":"12","author":"C Peng","year":"2019","unstructured":"Peng C, et al. Hypoxia-induced upregulation of HE4 Is responsible for resistance to radiation therapy of gastric cancer. Mol Ther Oncolytics. 2019;12:49\u201355.","journal-title":"Mol Ther Oncolytics"},{"key":"1665_CR28","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/s12859-018-2486-6","volume":"19","author":"SX Ge","year":"2018","unstructured":"Ge SX, et al. iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data. BMC Bioinformatics. 2018;19:534.","journal-title":"BMC Bioinformatics"},{"key":"1665_CR29","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3390\/cancers10090337","volume":"10","author":"AP Nayak","year":"2018","unstructured":"Nayak AP, et al. Oxidative phosphorylation: a target for novel therapeutic strategies against ovarian cancer. Cancers (Basel). 2018;10:337.","journal-title":"Cancers (Basel)"},{"key":"1665_CR30","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/cdd.2016.39","volume":"23","author":"DS Matassa","year":"2016","unstructured":"Matassa DS, et al. Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer. Cell Death Differ. 2016;23:1542\u201354.","journal-title":"Cell Death Differ"},{"key":"1665_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2020.112369","author":"L Shen","year":"2020","unstructured":"Shen L, et al. PGC1\u03b1 regulates mitochondrial oxidative phosphorylation involved in cisplatin resistance in ovarian cells via nucleo-mitochondrial transcriptional feedback. Exp Cell Res. 2020. https:\/\/doi.org\/10.1016\/j.yexcr.2020.112369.","journal-title":"Exp Cell Res"},{"key":"1665_CR32","doi-asserted-by":"crossref","first-page":"8760","DOI":"10.1038\/s41598-017-09206-0","volume":"7","author":"S Dar","year":"2017","unstructured":"Dar S, et al. Bioenergetic adaptations in chemoresistant ovarian cancer cells. Sci Rep. 2017;7:8760.","journal-title":"Sci Rep"},{"key":"1665_CR33","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.18632\/oncotarget.2010","volume":"5","author":"A Past\u00f2","year":"2014","unstructured":"Past\u00f2 A, et al. Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation. Oncotarget. 2014;5:4305\u201319.","journal-title":"Oncotarget"},{"key":"1665_CR34","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ygyno.2017.01.015","volume":"144","author":"BJ Winterhoff","year":"2017","unstructured":"Winterhoff BJ, et al. Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells. Gynecol Oncol. 2017;144:598\u2013606.","journal-title":"Gynecol Oncol"},{"key":"1665_CR35","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.3390\/microorganisms8111718","volume":"8","author":"A Schirinzi","year":"2020","unstructured":"Schirinzi A, et al. New insights in laboratory testing for COVID-19 patients: looking for the role and predictive value of human epididymis secretory protein 4 (HE4) and the innate immunity of the oral cavity and respiratory tract. Microorganisms. 2020;8:1718.","journal-title":"Microorganisms"},{"key":"1665_CR36","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fphar.2019.00216","volume":"10","author":"NE James","year":"2019","unstructured":"James NE, et al. Human epididymis secretory protein 4 (HE4) compromises cytotoxic mononuclear cells via inducing dual specificity phosphatase 6. Front Pharmacol. 2019;10:216.","journal-title":"Front Pharmacol"},{"key":"1665_CR37","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/cei.13153","volume":"193","author":"NE James","year":"2018","unstructured":"James NE, et al. HE4 suppresses the expression of osteopontin in mononuclear cells and compromises their cytotoxicity against ovarian cancer cells. Clin Exp Immunol. 2018;193:327\u201340.","journal-title":"Clin Exp Immunol"},{"key":"1665_CR38","first-page":"456","volume":"64","author":"M Bickel","year":"1993","unstructured":"Bickel M. The role of interleukin-8 in inflammation and mechanisms of regulation. J Periodontol. 1993;64:456\u201360.","journal-title":"J Periodontol"},{"key":"1665_CR39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.addr.2017.07.014","volume":"121","author":"MA Karsdal","year":"2017","unstructured":"Karsdal MA, et al. The good and the bad collagens of fibrosis - their role in signaling and organ function. Adv Drug Deliv Rev. 2017;121:43\u201356.","journal-title":"Adv Drug Deliv Rev"},{"key":"1665_CR40","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/carcin\/bgi242","volume":"27","author":"C van Waveren","year":"2006","unstructured":"van Waveren C, et al. Oxidative phosphorylation dysfunction modulates expression of extracellular matrix\u2013remodeling genes and invasion. Carcinogenesis. 2006;27:409\u201318.","journal-title":"Carcinogenesis"},{"key":"1665_CR41","doi-asserted-by":"crossref","first-page":"17094","DOI":"10.1038\/s41598-018-35381-9","volume":"8","author":"EJ Mah","year":"2018","unstructured":"Mah EJ, et al. Collagen density modulates triple-negative breast cancer cell metabolism through adhesion-mediated contractility. Sci Rep. 2018;8:17094.","journal-title":"Sci Rep"},{"key":"1665_CR42","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.18632\/oncotarget.27822","volume":"11","author":"DA Landry","year":"2020","unstructured":"Landry DA, et al. The significance of ovarian fibrosis. Oncotarget. 2020;11:4366\u201370.","journal-title":"Oncotarget"},{"key":"1665_CR43","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12931-016-0420-x","volume":"17","author":"N Sato","year":"2016","unstructured":"Sato N, et al. Metformin attenuates lung fibrosis development via NOX4 suppression. Respir Res. 2016;17:107.","journal-title":"Respir Res"},{"key":"1665_CR44","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1042\/BJ20140620","volume":"462","author":"HR Bridges","year":"2014","unstructured":"Bridges HR, et al. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J. 2014;462:475\u201387.","journal-title":"Biochem J"},{"key":"1665_CR45","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1593\/neo.11148","volume":"13","author":"R Rattan","year":"2011","unstructured":"Rattan R, et al. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia. 2011;13:483\u201391.","journal-title":"Neoplasia"},{"key":"1665_CR46","doi-asserted-by":"crossref","first-page":"27034","DOI":"10.18632\/oncotarget.15067","volume":"8","author":"TME Modica","year":"2017","unstructured":"Modica TME, et al. The extracellular matrix protein EMILIN1 silences the RAS-ERK pathway via \u03b14\u03b21 integrin and decreases tumor cell growth. Oncotarget. 2017;8:27034\u201346.","journal-title":"Oncotarget"},{"key":"1665_CR47","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"1665_CR48","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004088","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical. Sci Signal. 2013. https:\/\/doi.org\/10.1126\/scisignal.2004088.","journal-title":"Sci Signal"},{"key":"1665_CR49","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi M, et al. Next-generation characterization of the cancer cell line encyclopedia. Nature. 2019;569:503\u20138.","journal-title":"Nature"},{"key":"1665_CR50","unstructured":"Team, R.C. (2013) R: a language and environment for statistical computing."},{"key":"1665_CR51","unstructured":"Morgan, M. and Davis, S. R: a language and environment for statistical computing, NIH\/NCI Genomic Data Commons Access. [Online]. Available: https:\/\/bioconductor.org\/packages\/GenomicDataCommons, http:\/\/github.com\/Bioconductor\/GenomicDataCommons. Accessed 15 Jun 2020."},{"key":"1665_CR52","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284\u20137.","journal-title":"OMICS"},{"key":"1665_CR53","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/bioinformatics\/btu684","volume":"31","author":"G Yu","year":"2015","unstructured":"Yu G, et al. DOSE: an R\/Bioconductor package for disease ontology semantic and enrichment analysis. Bioinformatics. 2015;31:608\u20139.","journal-title":"Bioinformatics"},{"key":"1665_CR54","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/wics.1383","volume":"8","author":"A Datta","year":"2016","unstructured":"Datta A, et al. On nearest-neighbor Gaussian process models for massive spatial data. Wiley Interdiscip Rev Comput Stat. 2016;8:162\u201371.","journal-title":"Wiley Interdiscip Rev Comput Stat"},{"key":"1665_CR55","unstructured":"Carlson, M. (2019) org.Hs.eg.db: Genome wide annotation for Human, R package version 3.8.2."},{"key":"1665_CR56","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1530\/ERC-11-0329","volume":"19","author":"B Gyorffy","year":"2012","unstructured":"Gyorffy B, et al. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012;19:197\u2013208.","journal-title":"Endocr Relat Cancer"},{"key":"1665_CR57","doi-asserted-by":"crossref","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48:W509\u201314.","journal-title":"Nucleic Acids Res"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01665-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-022-01665-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01665-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T03:06:05Z","timestamp":1744167965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-022-01665-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,15]]},"references-count":57,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["1665"],"URL":"https:\/\/doi.org\/10.1007\/s12032-022-01665-4","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,15]]},"assertion":[{"value":"27 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"71"}}